Navigation Links
Millions with Arthritis May Benefit from Bone Loss Drug

People taking a widely used medication to strengthen fragile, aging bones may also be protecting their joints, according to a recent study led by Johns Hopkins// rheumatologist Clifton Bingham, M.D.

Researchers began to wonder if risedronate might be used to treat osteoarthritis after noticing that the drug, and other compounds in the same class of drugs, not only slowed joint damage in animals, but also reduced cartilage-irritating bone lesions in humans.

For two years, an international team of investigators studied 2,483 arthritic men and women, from both the United States and Europe. All of those enrolled in the study had a loss in the cartilage that cushions the knee joint, a hallmark symptom of osteoarthritis.

Reporting in the most recent issue of the medical journal Arthritis & Rheumatism, Bingham and his team said study participants were given either a placebo or risedronate at a range of doses, including the standard doses normally prescribed to treat bone loss. The amount of cartilage detected in their knees was measured by X-ray analysis at the one- and two-year marks. Blood tests were also used to check for a marker of cartilage breakdown known as CTX-II.

CTX-II is released in the bloodstreams of people with osteoarthritis when cartilage begins to fray. How fast and to what degree cartilage breaks down can be approximated by levels of CTX-II.

“The blood tests revealed not only that risedronate stabilized bone loss, but also that it was most likely slowing the breakdown of cartilage, too” says Bingham.

Bingham emphasizes that X-rays failed to show any dramatic visible changes in the structure of the joints with risedronate compared to a placebo: however, the numbers of patients exhibiting significant progression of the disease were few in all treatment groups. A great challenge now is identifying the risk factors for joint deterioration in osteoarthritis, adds Bingham.

T he investigators also did not see a significant reduction in joint pain with risedronate compared with the placebo.

In the United States, where an estimated 25 million people have osteoarthritis and 44 million have osteoporosis, participants in the study group taking risedronate experienced a noticeable drop in their CTX-II levels: 17.9 percent. The Europeans fared even better, with a 19.6 percent decrease. Patients taking the drug at normal levels and at higher than usual doses given for comparison experienced similar slowdowns in cartilage decline, without significant adverse side effects.

Those in the placebo group, however, experienced increases in CTX-II levels (26.3 percent for the Americans and 10.1 percent for the Europeans), suggesting that their cartilage was deteriorating faster than that in those taking the drug.

“We are not recommending that everyone with arthritis run out and get a prescription for these kinds of drugs, nor are we suggesting at this time that doctors use risedronate as an arthritis treatment,” cautions Bingham. “But what we can say now is that drugs affecting bone turnover need to be further evaluated for their potential effects as arthritis therapies.”

The blood test changes seen in the study would suggest that people already taking bone strengthening drugs may be simultaneously helping their joints, concludes Bingham.

Source-Newswie

'"/>




Related medicine news :

1. Drug May Make Breathing Easier for Millions
2. Proper Validation of Generic Drugs Could Save Millions of AIDS Patients
3. Decoding the Fungi Genome Will Save Millions of Lives.
4. Millions Of Diabetic And Glaucoma Patients Risk Blindness
5. Early Detection Of Primary Liver Cancer Would Save Millions Of Lives
6. WHO Attributes Death of Millions in Africa to Treatable diseases
7. Toll of a Potential Flu Pandemic Runs into Millions
8. NHS Could Save Millions Through Generic Drugs
9. Glaucoma: Silently Stealing Sight from Millions
10. Easy Money-NHS Trusts Make Millions from Parking Fees
11. Ladakh was a Coastal Region Millions of Years Ago
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/24/2017)... ... April 24, 2017 , ... ... PA will be attending the 2017 Oral Reconstruction Foundation’s 2017 Symposium on Tissue ... Oral Reconstruction Foundation will present its annual Global Symposium at the Fontainebleau Hotel ...
(Date:4/24/2017)... ... April 24, 2017 , ... Anaconda BioMed, a ... systems for the treatment of Acute Ischemic Stroke (AIS), today announced it has ... the product advances towards regulatory and clinical phases. , "This is another important ...
(Date:4/23/2017)... CA (PRWEB) , ... April 23, 2017 , ... ... solutions and managed services announced the achievement of Cisco Select certification and SMB ... throughout the United States. , In earning the Select Certification, Altura ...
(Date:4/22/2017)... ... April 22, 2017 , ... PharmacyChecker.com ... can save an average of 70% when buying medication online from Canadian pharmacies ... available when purchasing from other countries. The report (chart below) compares U.S. and ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... An April ... of a pair of ancient teeth, which reveal a great deal about prehistoric ice-age ... a sharp stone may have been used to remove decayed dental matter, and that ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key ... to their offering. ... global pharmacogenomics market was valued at US$ 7,167.6 Mn in ... 2024, expanding at a CAGR of 5.6% from 2016 to ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
(Date:4/19/2017)... -- The Mobile X-Ray product segment is the most attractive ... forecast period Mobile X-Ray segment is the largest ... devices market, which is estimated to be valued at more ... of 7% over the forecast period. Mobile X-Ray segment is ... 100 Mn in 2017 over 2016. The segment,s revenue in ...
Breaking Medicine Technology: